Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human α1-antitrypsin

European Journal of Clinical Pharmacology

Volumn 59, Issue 2, 2003, Pages 151-156

  Piitulainen, Eeva ^a   Bernspång, Elisabeth ^a   Björkman, Sven ^a   Berntorp, Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Augmentation therapy; Emphysema; Human 1 antitrypsin; Pharmacokinetics; 1 Antitrypsin deficiency

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE PREDISPOSITION; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG INFUSION; DRUG SELF ADMINISTRATION; EMPHYSEMA; FEMALE; HEALTH CARE COST; HOME CARE; HUMAN; IMPLANTABLE PORT SYSTEM; MALE; OPEN STUDY; PRIORITY JOURNAL;

EID: 0038391385     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0589-z     Document Type: Article

References (20)

1. 1-antitrypsin deficiency, PiZ. Acta Med Scand 204:345-351
2. 1-antitrypsin deficiency (PiZZ). Eur Respir J 13:247-251
3. Janoff A (1985) Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 132:417-433
4. 1-antitrypsin deficiency associated with emphysema. N Engl J Med 316:1055-1062
5. Schwaiblmair M, Vogelmeier C, Fruhmann G (1997) Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency - three-year follow-up. Respiration 64:10-15
6. 1-antitrypsin deficiency. Chest 119:745-752
7. 1-antitrypsin deficiency. JAMA 260:1259-1264
8. 1-antitrypsin deficiency. Chest 112:607-613
9. Berntorp E (1995) Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment. Haemophilia 1 [Suppl 1]:3-7
10. Ljung R, van den Berg M, Petrini P, Tengborn L, Scheibel E, Kekomaki R, Effenberger W (1998) Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 87:1051-1054
11. 1-antitrypsin deficiency. Haematology 9:173-178
12. Berglund E, Birath G, Bjure J, Gimby G, Kjellmer I, Sandkvist L, Söderholm B (1963) Spirometric studies in normal subjects. Acta Med Scand 173:185-191
13. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
14. Carlsson M, Berntorp E, Björkman S, Lindvall K (1993) Pharmacokinetic dosing in prophylactic treatment of haemophilia A. Eur J Haematol 51:247-252
15. Carlsson M, Björkman S, Berntorp E (1998) Multidose pharmacokinetics of factor IX. Implications for dosing in prophylaxis. Haemophilia 4:83-88
16. Thompson GA, Schumaker RC (1989-1990) MLTIDOSE: a multiple-dose simulation program for linear systems characterized by exponential functions. Drug Metab Rev 21:463-469
17. 1-antitrypsin, Respitin. Chest 122:66-74
18. 1-antitrypsin. J Lab Clin Med 75:742-745
19. 1-antitrypsin of Pi type M and Z in man. Clin Sci Mol Med 52:457-461
20. 1-antitrypsin. Clin Sci Mol Med 55:139-148